Holen Sie sich die Stockscreener-App
0.6706
9.74%
-0.0724
Schlusskurs vom Vortag:
$0.743
Offen:
$0.721
24-Stunden-Volumen:
252.83K
Relative Volume:
0.14
Marktkapitalisierung:
$2.27M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-30.11%
1M Leistung:
-63.75%
6M Leistung:
-84.03%
1J Leistung:
-92.34%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.6563
$1.0039
52-Wochen-Spanne:
$0.6563
$9.17
Kairos Pharma, Ltd. Stock (KAPA) Company Profile
Firmenname
Kairos Pharma, Ltd.
Sektor
Branche
Telefon
-
Adresse
-
Compare KAPA vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KAPA
Kairos Pharma, Ltd.
|
0.6706 | 2.27M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kairos Pharma, Ltd. Aktie (KAPA) Neueste Nachrichten
Kairos Pharma reports positive interim data for prostate cancer trial By Investing.com - Investing.com Nigeria
Why Is Kairos Pharma Stock Falling Today?Kairos Pharma (AMEX:KAPA) - Benzinga
Kairos Pharma reports positive interim data for prostate cancer trial - Investing.com
What's Moving Biotech Stocks Pre-Market? Bluejay Diagnostics (NASDAQ:BJDX), Kairos Pharma (NYSE:KAPA), Rezolute (NASDAQ:RZLT) in Focus - kalkine.ca
Kairos Pharma reports positive interim data for prostate cancer trial By Investing.com - Investing.com Canada
Kairos Pharma reports positive Phase 2 interim PFS data; median PFS 17.7 vs 2 months - TradingView
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA - Yahoo Finance
Kairos (KAPA) Soars +3.47% Past $1.88 — New Highs Ahead? 2026-09-22Call Flow Alert - dars.gov.et
Kairos Pharma (AMEX: KAPA) Releases Investor Presentation on September 14 at H.C. Wainwright Conference - Kalkine Media
Kairos Pharma at H.C. Wainwright conference: resistance strategy in focus By Investing.com - Investing.com UK
Kairos Pharma (KAPA) to present clinical update at H.C. Wainwright investor conference - stocktitan.net
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance
Kairos Pharma Announces 1-for-7 Reverse Stock Split to Meet NYSE American Listing Rules - Minichart
Kairos Pharma Announces 1-for-7 Reverse Stock Split - Yahoo Finance
Kairos Pharma to conduct 1-for-7 reverse stock split By Investing.com - Investing.com Canada
Kairos Pharma to Conduct 1-for-7 Reverse Stock Split - Yahoo Finance
Kairos Pharma to conduct 1-for-7 reverse stock split - Investing.com
Kairos (KAPA) Results Breakdown: EPS Falls Short of Its Estimate under the Current Snapshot; Latest Reaction: Shares Move 1.52% Lower on the DayEarnings Surprise Stocks - careplusvn.com
Kairos (KAPA) Results Check: Reported EPS Misses Expectations in the Reported Period; Price Reaction: The Stock Ends Down 4.68% in Latest TradingFiscal Year Earnings - careplusvn.com
Kairos Pharma (KAPA) Slips 1.07% to $0.35 as Biotech Consolidation Keeps $0.33 Support in FocusStock Analysis - careplusvn.com
KAPA Q1 2026 Earnings: EPS Misses Estimates Amid Pre-Clinical Stage OperationsSaaS Earnings Trends - careplusvn.com
KAPA Q1 2026 Earnings: Narrow Loss Slightly Misses Estimates; Shares Climb 3.71%Earnings Whisper Number - careplusvn.com
Kairos Pharma (KAPA) Tests Support as Stock Slides to $0.29Volume Nodes - careplusvn.com
Kairos Pharma partners with Bayer on prostate cancer study - Investing.com
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer - Yahoo Finance
Kairos Pharma Sees Significant Decline as Stock Approaches Key Support LevelCounter Trend Trade - careplusvn.com
Kairos Pharma Sees Significant Decline as Stock Approaches Key Support LevelProtective Put - dars.gov.et
Kairos Pharma Ltd. (KAPA) Drops 8.8%, Approaches Key Support LevelBear Flag - careplusvn.com
Kairos Pharma (KAPA) Stock Surges Over 22% After Hours: Why is it Moving? - Benzinga
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever - tradingview.com
KAPA Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues DevelopmentFiscal Year Earnings - careplusvn.com
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy - Yahoo Finance
Should I buy Kairos Pharma, Ltd. (KAPA) - Zacks Investment Research
Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders - Lelezard
KAPA - Finviz
Kairos Pharma | DEF 14A: Definitive information statements - Moomoo
Kairos Pharma, Ltd. to Present at the LD Micro Invitational XVI - TMX Newsfile
Kairos Pharma, LTD. 1Q 2026: Revenue $0 Net loss $(1.65M) — 10-Q Summary - tradingview.com
Kairos Pharma, Ltd. Sets Annual Meeting of Shareholder Date and Provides Update on Its Annual Filings - Yahoo Finance
Kairos Pharma Investor News: Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA - Business Wire
Rosen Law Firm Encourages Kairos Pharma, Ltd. Investors to Inquire About Securities Class Action Investigation – KAPA - Business Wire
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Pharmaceutical Technology
Kairos Pharma acquires lung cancer drug assets from Celyn Therapeutics - Mugglehead Investment Magazine
Kairos Pharma (KAPA) Institutional Ownership 2026 - MarketBeat
Kairos Pharma Wins R&D Award for Innovative Advanced Prostate Cancer Trial with ENV 105 - Clinical Trials Arena
What is the current Price Target and Forecast for Kairos Pharma, Ltd. (KAPA) - Zacks Investment Research
Kairos Pharma, Ltd. (KAPA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Kairos Pharma, Ltd. (KAPA) stock price, news, quote and history - Yahoo Finance UK
Finanzdaten der Kairos Pharma, Ltd.-Aktie (KAPA)
Es liegen keine Finanzdaten für Kairos Pharma, Ltd. (KAPA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):